• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

康士得（ICI 176,334），一种新型非甾体类抗雄激素药物。早期临床结果。

Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results.

作者信息

Lunglmayr G

机构信息

Department of Urology, Mistelbach General Infirmary, Austria.

出版信息

Horm Res. 1989;32 Suppl 1:77-81. doi: 10.1159/000181316.

DOI:10.1159/000181316
PMID:2515147
Abstract

Following promising results in animal studies, Casodex (ICI 176,334) has been studied in the treatment of patients with advanced prostate cancer. At doses of 10, 30 and 50 mg, the drug was found to be well tolerated, with a moderate effect on sex hormone levels. The 50 mg dose of Casodex (daily) reduced previously elevated acid phosphatase levels by 50% or more in 71% of patients.

摘要

在动物研究取得有前景的结果后，已对康士得（ICI 176,334）治疗晚期前列腺癌患者进行了研究。在10毫克、30毫克和50毫克的剂量下，该药物耐受性良好，对性激素水平有中度影响。50毫克剂量的康士得（每日）使71%的患者先前升高的酸性磷酸酶水平降低了50%或更多。

相似文献

1
Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results.康士得（ICI 176,334），一种新型非甾体类抗雄激素药物。早期临床结果。
Horm Res. 1989;32 Suppl 1:77-81. doi: 10.1159/000181316.
2
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
Eur Urol. 1998;33(1):39-53. doi: 10.1159/000019526.
3
Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.新型非甾体抗雄激素药物康士得治疗前列腺癌期间的内分泌情况
Clin Endocrinol (Oxf). 1994 Oct;41(4):525-30. doi: 10.1111/j.1365-2265.1994.tb02585.x.
4
Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators.新型抗雄激素药物康士得（ICI 176,334）单药治疗试验的最新情况。国际康士得研究人员。
Eur Urol. 1994;26 Suppl 1:5-9.
5
[Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].[醋酸阿比特龙在激素抵抗性前列腺癌患者中的初步应用结果]
Urologiia. 2001 Nov-Dec(6):20-1.
6
Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer.康士得：一种纯非甾体类抗雄激素药物，用于晚期前列腺癌的单一疗法。
Prostate Suppl. 1992;4:97-104. doi: 10.1002/pros.2990210515.
7
Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.抗雄激素药物康士得（ICI 176,334）单药治疗前列腺癌的耐受性及生活质量方面。国际康士得研究人员
Eur Urol. 1994;26 Suppl 1:15-9. doi: 10.1159/000475426.
8
[Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].[剂量为150毫克的康士得单一疗法——一种治疗播散性前列腺癌的新激素治疗方法]
Urologiia. 2002 Sep-Oct(5):23-6.
9
"Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
Horm Res. 1989;32 Suppl 1:69-76. doi: 10.1159/000181315.
10
[Monitoring of erection function in patients with prostatic carcinoma treated with Casodex].[用康士得治疗的前列腺癌患者勃起功能监测]
Arch Ital Urol Nefrol Androl. 1991 Mar;63(1):155-61.

引用本文的文献

1
Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on.八十年来针对前列腺癌雄激素受体活性的研究：战斗仍在继续。
Cancers (Basel). 2021 Jan 29;13(3):509. doi: 10.3390/cancers13030509.
2
Bicalutamide: clinical pharmacokinetics and metabolism.比卡鲁胺：临床药代动力学与代谢
Clin Pharmacokinet. 2004;43(13):855-78. doi: 10.2165/00003088-200443130-00003.
3
Pathological and morphometric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176,334) or bilateral orchidectomy.
Urol Res. 1994;22(3):191-5. doi: 10.1007/BF00571849.